{
    "2018-01-25": [
        [
            {
                "time": "2017-01-01",
                "original_text": "GlaxoSmithKline Could Witness Modest Rise in Revenues in 2017",
                "features": {
                    "keywords": [
                        "GlaxoSmithKline",
                        "modest rise",
                        "revenues"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2017-01-01",
                "original_text": "Biogen Revenue Tops As Spinraza, MS Drugs Deliver Upside",
                "features": {
                    "keywords": [
                        "Biogen",
                        "Spinraza",
                        "MS drugs",
                        "upside"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2017-01-01",
                "original_text": "Celgene Reverses In Fourth Quarter As Otezla Sales Rebound",
                "features": {
                    "keywords": [
                        "Celgene",
                        "fourth quarter",
                        "Otezla sales",
                        "rebound"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-01",
                "original_text": "What Analysts Recommend for GlaxoSmithKline in January 2018",
                "features": {
                    "keywords": [
                        "analysts",
                        "recommend",
                        "GlaxoSmithKline"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-01",
                "original_text": "Taking Stock of Radius Health’s Licensing Agreements",
                "features": {
                    "keywords": [
                        "Radius Health",
                        "licensing agreements"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-01",
                "original_text": "Trump speaks with leaders from Total, Novartis and others...",
                "features": {
                    "keywords": [
                        "Trump",
                        "Total",
                        "Novartis",
                        "leaders"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "energy",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-01",
                "original_text": "A Strong Pipeline of Drugs Bodes Well for Radius Health",
                "features": {
                    "keywords": [
                        "pipeline",
                        "drugs",
                        "Radius Health"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2017-01-01",
                "original_text": "European ADRs Move Higher in Thursday Trading",
                "features": {
                    "keywords": [
                        "European ADRs",
                        "higher",
                        "trading"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "finance"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-01",
                "original_text": "Analysts’ Ratings for Radius Health and Its Peers in January",
                "features": {
                    "keywords": [
                        "analysts",
                        "ratings",
                        "Radius Health",
                        "peers"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-01",
                "original_text": "How Is Novartis’s Tafinlar+Mekinist Positioned for 2018?",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Tafinlar",
                        "Mekinist",
                        "positioned"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2017-01-01",
                "original_text": "Analysts’ Estimates for Pfizer’s 4Q17 Earnings",
                "features": {
                    "keywords": [
                        "analysts",
                        "estimates",
                        "Pfizer",
                        "earnings"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-01",
                "original_text": "Tasigna Could Boost Novartis’s Revenue Growth in 2018",
                "features": {
                    "keywords": [
                        "Tasigna",
                        "Novartis",
                        "revenue growth"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-01",
                "original_text": "Novartis Receives 2 Breakthrough Therapy Designations in January",
                "features": {
                    "keywords": [
                        "Novartis",
                        "breakthrough therapy",
                        "designations"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2017-01-01",
                "original_text": "The Swiss Stock Market Pulled Back After ECB Announcement",
                "features": {
                    "keywords": [
                        "Swiss stock market",
                        "ECB",
                        "announcement"
                    ],
                    "sentiment_score": 0.3,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "finance"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-01",
                "original_text": "Spark licenses blindness gene therapy rights outside U.S. to Novartis",
                "features": {
                    "keywords": [
                        "Spark",
                        "blindness",
                        "gene therapy",
                        "Novartis"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}